Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Revenue of Regulus Therapeutics Inc. (RGLS)
Revenue in 2023 (TTM): $
According to Regulus Therapeutics Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Regulus Therapeutics Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-21,152,000 | $-30,882,000 | $-30,036,000 | $-30,037,000 |
| 2022 | $ | $-122,000 | $-28,239,000 | $-28,322,000 | $-28,323,000 |
| 2021 | $ | $-459,000 | $-27,816,000 | $-27,807,000 | $-27,808,000 |
| 2020 | $10.01 M | $9.99 M | $-14,155,000 | $-15,730,000 | $-15,263,000 |
| 2019 | $6.83 M | $6.82 M | $-16,834,000 | $-18,591,000 | $-18,592,000 |
| 2018 | $72 K | $-33,903,000 | $-46,763,000 | $-48,647,000 | $-48,709,000 |
| 2017 | $72 K | $-54,519,000 | $-68,160,000 | $-72,102,000 | $-71,905,000 |
| 2016 | $1.19 M | $-63,111,000 | $-81,164,000 | $-81,840,000 | $-81,836,000 |
| 2015 | $20.76 M | $-35,628,000 | $-53,750,000 | $-55,766,000 | $-55,748,000 |
| 2014 | $7.67 M | $-33,377,000 | $-33,141,000 | $-56,679,000 | $-56,680,000 |
| 2013 | $19.57 M | $-10,373,000 | $-16,913,000 | $-18,691,000 | $-18,668,000 |
| 2012 | $12.7 M | $12.68 M | $-11,447,000 | $-17,418,000 | $-17,408,000 |
| 2011 | $13.79 M | $13.79 M | $-6,098,000 | $-7,396,000 | $-7,602,000 |
| 2010 | $8.6 M | $8.6 M | $-14,733,000 | $-15,589,000 | $-15,559,000 |